NCT06717269View on ClinicalTrials.gov

Relative Bioavailability of NX-5948 Tablets Vs Capsules and the Effect of Covariates on the PK of NX-5948 Tablets

PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 30, 2024

Primary Completion Date

February 15, 2025

Study Completion Date

March 31, 2025

Conditions
Healthy Volunteer
Interventions
DRUG

NX-5948 capsule

NX-5948 in capsule form

DRUG

NX-5948 tablet

NX-5948 in tablet form

DRUG

Esomeprazole

Esomeprazole capsule, once daily

Trial Locations (1)

68502

RECRUITING

Celerion, Lincoln

Sponsors
All Listed Sponsors
lead

Nurix Therapeutics, Inc.

INDUSTRY

NCT06717269 - Relative Bioavailability of NX-5948 Tablets Vs Capsules and the Effect of Covariates on the PK of NX-5948 Tablets | Biotech Hunter | Biotech Hunter